| Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease NK Majbour, NN Vaikath, KD Van Dijk, MT Ardah, S Varghese, ... Molecular neurodegeneration 11, 1-15, 2016 | 278 | 2016 |
| Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease O Hansson, S Hall, A Öhrfelt, H Zetterberg, K Blennow, L Minthon, ... Alzheimer's research & therapy 6, 1-6, 2014 | 233 | 2014 |
| Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration MF Duffy, TJ Collier, JR Patterson, CJ Kemp, KC Luk, MG Tansey, ... Journal of neuroinflammation 15, 1-18, 2018 | 225 | 2018 |
| Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease L Parnetti, L Farotti, P Eusebi, D Chiasserini, C De Carlo, D Giannandrea, ... Frontiers in aging neuroscience 6, 53, 2014 | 195 | 2014 |
| Parkinson’s disease biomarkers based on α‐synuclein M Fayyad, S Salim, N Majbour, D Erskine, E Stoops, B Mollenhauer, ... Journal of neurochemistry 150 (5), 626-636, 2019 | 184 | 2019 |
| Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice M Karampetsou, MT Ardah, M Semitekolou, A Polissidis, M Samiotaki, ... Scientific reports 7 (1), 16533, 2017 | 183 | 2017 |
| Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology NN Vaikath, NK Majbour, KE Paleologou, MT Ardah, E van Dam, ... Neurobiology of disease 79, 81-99, 2015 | 163 | 2015 |
| Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial D Volc, W Poewe, A Kutzelnigg, P Lührs, C Thun-Hohenstein, ... The Lancet Neurology 19 (7), 591-600, 2020 | 139 | 2020 |
| Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression NK Majbour, NN Vaikath, P Eusebi, D Chiasserini, M Ardah, S Varghese, ... Movement Disorders 31 (10), 1535-1542, 2016 | 129 | 2016 |
| α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity SS Ghanem, NK Majbour, NN Vaikath, MT Ardah, D Erskine, NM Jensen, ... Proceedings of the National Academy of Sciences 119 (15), e2109617119, 2022 | 121 | 2022 |
| Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice M Helwig, M Klinkenberg, R Rusconi, RE Musgrove, NK Majbour, ... Brain 139 (3), 856-870, 2016 | 112 | 2016 |
| α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies I van Steenoven, NK Majbour, NN Vaikath, HW Berendse, ... Movement Disorders 33 (11), 1724-1733, 2018 | 104 | 2018 |
| Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy O El-Agnaf, C Overk, E Rockenstein, M Mante, J Florio, A Adame, ... Neurobiology of disease 104, 85-96, 2017 | 100 | 2017 |
| CSF or serum neurofilament light added to α‐synuclein panel discriminates Parkinson's from controls LP Oosterveld, IMW Verberk, NK Majbour, OM El‐Agnaf, HC Weinstein, ... Movement Disorders 35 (2), 288-295, 2020 | 85 | 2020 |
| Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers JO Aasly, KK Johansen, G Brønstad, BJ Warø, NK Majbour, S Varghese, ... Frontiers in aging neuroscience 6, 248, 2014 | 79 | 2014 |
| Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects JJ Tomlinson, B Shutinoski, L Dong, F Meng, D Elleithy, NA Lengacher, ... Journal of neural transmission 124, 721-738, 2017 | 64 | 2017 |
| Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease NK Majbour, D Chiasserini, NN Vaikath, P Eusebi, T Tokuda, ... Scientific reports 7 (1), 40263, 2017 | 61 | 2017 |
| CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers NK Majbour, JO Aasly, E Hustad, MA Thomas, NN Vaikath, N Elkum, ... Translational neurodegeneration 9, 1-10, 2020 | 52 | 2020 |
| RETRACTED: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders H Javed, SA Menon, KM Al-Mansoori, A Al-Wandi, NK Majbour, MT Ardah, ... Molecular Therapy 24 (4), 746-758, 2016 | 52 | 2016 |
| A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein N Landeck, H Hall, MT Ardah, NK Majbour, OMA El-Agnaf, G Halliday, ... Molecular neurodegeneration 11, 1-23, 2016 | 44 | 2016 |